Giovanni Taverna

Dr. Giovanni Taverna

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Medicina
Verified
Journal Article
Open access
PDF file
Giancarlo TrimarchiGiancarlo Trimarchi
Giancarlo Trimarchi
MCMaria Ludovica Carerj
Maria Ludovica Carerj
Concetta ZitoConcetta Zito
Concetta Zito
GBGianluca Di Bella
Gianluca Di Bella
GTGiovanni Taverna
Giovanni Taverna
SCScipione Carerj
Scipione Carerj
Epicardial adipose tissue (EAT), strategically located between the myocardium and the visceral pericardial layer, is increasingly recognized as an active player in cardiovascular health rather than a passive fat depot. EAT secretes a notable array of bioactive molecules known as adipokines, which exert critical exocrine and paracrine effects. Recent research has focused on pericoronary adipose tissue (PCAT)—the EAT surrounding coronary arteries—demonstrating its intricate bidirectional relationship with the vascular wall. Under normal physiological conditions, this interaction promotes vascular homeostasis; however, dysfunctional PCAT can release pro-inflammatory adipokines implicated in the pathogenesis of atherogenesis. Notably, PCAT inflammation has emerged as a significant factor associated with the development of coronary artery disease (CAD) and major cardiovascular events. This review seeks to elucidate the imaging methodologies employed to evaluate EAT, emphasizing cardiac computed tomography (CCT) as the preeminent imaging modality. Unlike echocardiography and cardiac magnetic resonance imaging, CCT not only visualizes and quantifies EAT but also concurrently assesses coronary arteries and PCAT. Recent findings have established the potential of CCT-derived PCAT attenuation as a noninvasive biomarker for coronary inflammation, offering prospects for monitoring therapeutic responses to innovative anti-inflammatory interventions in CAD management.

12 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
LTLucio Teresi
Lucio Teresi
Giancarlo TrimarchiGiancarlo Trimarchi
Giancarlo Trimarchi
RLRoberto Licordari
Roberto Licordari
DRDavide Restelli
Davide Restelli
GTGiovanni Taverna
Giovanni Taverna
GBGianluca Di Bella
Gianluca Di Bella
Among cardiomyopathies, the hypertrophic phenotype is the most common, and hypertrophic cardiomyopathy (HCM) phenocopies represent a heterogeneous group of conditions. They are defined by a left ventricular wall thickness ≥15 mm in the absence of other causes such as loading conditions, ischemia, or valvular disease. Although they mimic similar clinical and morphological features, their etiologies are distinct and include genetic, metabolic, and infiltrative mechanisms. Therefore, accurate classification and differential diagnosis are crucial for effective management and treatment. Sarcomeric HCM is the most frequent form, accounting for up to 60% of cases. However, numerous non-sarcomeric phenocopies exist, including amyloidosis, Fabry disease, glycogen storage disorders, RASopathies, and mitochondrial diseases. Clinical and imaging findings are essential to distinguish these entities from sarcomeric HCM. Electrocardiography, echocardiography, advanced modalities such as cardiac magnetic resonance (CMR), and specific laboratory tests all play a central role in guiding diagnosis. Genetic testing provides key insights into mutations and inheritance patterns, further supporting definitive diagnosis. Correct identification of an HCM phenocopy carries important therapeutic implications, as disease-specific treatments can significantly improve prognosis. For example, targeted therapies exist for amyloidosis, Fabry disease, and certain metabolic or mitochondrial disorders, underlining the clinical relevance of an accurate diagnosis. This review aims to provide an overview of HCM phenocopies and assist clinicians in diagnostic reasoning. The first part addresses classification according to pathophysiological mechanisms, clinical features, and genetic background. The second part focuses on the stepwise approach to differential diagnosis, integrating clinical assessment, laboratory evaluation, ECG, echocardiography, and CMR findings.

28 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
LTLucio Teresi
Lucio Teresi
Giancarlo TrimarchiGiancarlo Trimarchi
Giancarlo Trimarchi
RLRoberto Licordari
Roberto Licordari
DRDavide Restelli
Davide Restelli
GTGiovanni Taverna
Giovanni Taverna
GBGianluca Di Bella
Gianluca Di Bella
Among cardiomyopathies, the hypertrophic phenotype is the most common, and hypertrophic cardiomyopathy (HCM) phenocopies represent a heterogeneous group of conditions. They are defined by a left ventricular wall thickness ≥15 mm in the absence of other causes such as loading conditions, ischemia, or valvular disease. Although they mimic similar clinical and morphological features, their aetiologies are distinct and include genetic, metabolic, and infiltrative mechanisms. Therefore, accurate classification and differential diagnosis are crucial for effective management and treatment. Sarcomeric HCM is the most frequent form, accounting for up to 60% of cases. However, numerous non-sarcomeric phenocopies exist, including amyloidosis, Fabry disease, glycogen storage disorders, RASopathies, and mitochondrial diseases. Clinical and imaging findings are essential to distinguish these entities from sarcomeric HCM. Electrocardiography, echocardiography, advanced modalities such as cardiac magnetic resonance (CMR), and specific laboratory tests all play a central role in guiding diagnosis. Genetic testing provides key insights into mutations and inheritance patterns, further supporting definitive diagnosis. Correct identification of an HCM phenocopy carries important therapeutic implications, as disease-specific treatments can significantly improve prognosis. For example, targeted therapies exist for amyloidosis, Fabry disease, and certain metabolic or mitochondrial disorders, underlining the clinical relevance of an accurate diagnosis. This review aims to provide an overview of HCM phenocopies and assist clinicians in diagnostic reasoning. The first part addresses classification according to pathophysiological mechanisms, clinical features, and genetic background. The second part focuses on the stepwise approach to differential diagnosis, integrating clinical assessment, laboratory evaluation, ECG, echocardiography, and CMR findings.

9 January 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
GTGiovanni Taverna
Giovanni Taverna
LCLisa Canton
Lisa Canton
LZLorenza Zilio
Lorenza Zilio
VCVincenzo Calabrese
Vincenzo Calabrese
ACAnnagrazia Cecere
Annagrazia Cecere
MMMartina Perazzolo Marra
Martina Perazzolo Marra
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) demands prompt mechanistic clarification. Early integration of coronary CT angiography (CCTA) and cardiovascular magnetic resonance (CMR) can refine diagnosis during the acute phase. Methods: Twenty-one consecutive patients (41 ± 10 years; 71% men) presenting with troponin-positive chest pain and unobstructed coronaries underwent CCTA, delayed iodine-enhanced CT for late iodine enhancement (LIE), and CMR imaging within 14 days, with a mean interval of 5 days [interquartile range (IQR) 2–9] between both imaging modalities. CCTA assessed luminal stenosis and high-risk plaque; LIE mapped iodine retention; CMR evaluated myocardial edema and late gadolinium enhancement (LGE). Clinical, electrocardiographic, and laboratory data were collected. Results: Eight patients were classified as MINOCA and 13 as acute myocarditis. Chest pain was universal; dyspnea and syncope occurred in seven and two patients, respectively. Median peak high-sensitivity troponin-I was 1,569 ng/L (IQR 589–5 771). Biventricular systolic function was preserved (mean LVEF 58%; RVEF 55%). LGE appeared in 16 subjects: subendocardial in every MINOCA case and intramural or subepicardial in eight myocarditis cases. Myocardial edema was present in 15 patients. CCTA showed no atherosclerosis in 16 patients; five displayed non-obstructive lesions (<50% stenosis) with high-risk plaque confined to three MINOCA subjects. LIE confirmed iodine uptake matching the LGE pattern in all MINOCA patients and in six with myocarditis. Conclusions: An acute CCTA-CMR protocol may aid in distinguishing ischemic from non-ischemic myocardial injury in presumed MINOCA and unmasks occult high-risk plaques. This multimodal imaging approach reveals occult high-risk coronary plaques and enhances diagnostic accuracy, thereby supporting mechanism-targeted management strategies in patients presenting with troponin-positive chest pain.

6 February 2025 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
VCVincenzo Calabrese
Vincenzo Calabrese
RMRoberta Maria Messina
Roberta Maria Messina
VCValeria Cernaro
Valeria Cernaro
AFAlessandra Farina
Alessandra Farina
YPYlenia Di Pietro
Ylenia Di Pietro
Domenico SantoroDomenico Santoro
Domenico Santoro
Hypercalcemia is defined as a serum calcium concentration higher than 10.5 mg/gL or 2.6 mmol/L. Only 50% of serum calcium is active, presented as ionized calcium. The remaining half is bound to albumin, phosphate, and other serum anions, and their changes can affect the serum calcium concentration. Thus, to discriminate true hypercalcemia from pseudo hypercalcemia, an ionized calcium concentration higher than 1.3 mmol/L might be more appropriate. Many variables can lead to hypercalcemia, and managing them is necessary to treat this ion disorder. Indeed, it can be caused by malignancies, hematologic disorders, or genetic diseases such as familial hypocalciuric hypercalcemia, or it can be related to hormone disorders involving parathormone or vitamin D. For this condition, the correct diagnostic algorithm should be followed. In this review, we summarize the diagnostic steps to follow and detail each clinical pathway is involved in hypercalcemia.

19 May 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
Giuseppe SantarpinoGiuseppe Santarpino
Giuseppe Santarpino
GTGiovanni Taverna
Giovanni Taverna
VCVincenzo Calabrese
Vincenzo Calabrese
FCFlavia Coviello
Flavia Coviello
Giancarlo TrimarchiGiancarlo Trimarchi
Giancarlo Trimarchi
GSGiuseppe Speziale
Giuseppe Speziale
Background: The tricuspid valve (TV) is a complex three-dimensional (3D) anatomical structure; however, current guidelines recommend tricuspid annulus (TA) measurements to be performed with two-dimensional (2D) echocardiography. The aim of this study was to compare TV measurements obtained with 2D and four-dimensional (4D) echocardiography for surgical planning. Methods: All echocardiographic data of patients referred to our center for TV assessment were collected. Multimodality imaging data were reviewed, including 2D transthoracic echocardiography (TTE) integrated with information from 3D TTE. Measurements were also compared with those obtained using the 4D Auto Tricuspid Valve Quantification (TVQ) tool. Results: Overall, 11 patients (median age 72 [66–78] years, 18% female) were included in the study. Mild, moderate and severe tricuspid regurgitation (TR) was present in 6, 3 and 2 patients, respectively. Systolic pulmonary artery pressure was 35 ± 8 mmHg, inferior vena cava diameter 21 ± 4 mm, right atrial area 25 ± 9 cm2, 4D ejection fraction 45 ± 7%, 4D fractional area change 40 ± 6%, and tricuspid annular plane systolic excursion 21 [15–25] mm. 2D/4D right ventricular-basal diameter (RVD1) was significantly different (p < 0.005). Similarly, 2D/4D right ventricular diameter measured at the level of the left ventricular papillary muscles (RVD2) was significantly different (p < 0.012), as well as 2D/4D tricuspid annular diameter (p = 0.020). Despite these differences, a strong correlation between variables was observed (Spearman correlation coefficient >0.824). In evaluating the correlation between TR severity and analyzed variables, RVD1 was related to TR severity both at 2D and 4D echocardiography. Conversely, RVD2 and TA diameter were significantly associated with TR severity only at 4D echocardiography. Conclusions: Our results suggest that specific patient subsets could benefit more from TA measurements using the 4D Auto TVQ tool to help identify the mechanisms responsible for TR, including candidates for left-sided valve surgery and patients in whom the indication for TV repair is unclear.